Has David Snyder, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,280 in general payments to David Snyder, MD across 729 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Snyder, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Snyder, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Snyder, MD

Hematology & Oncology · Santa Fe, NMNPI 1487653176

Payments from drug & device makers

$13,280in general payments, 2019–2025

Across 729 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
AstraZeneca$1K
Johnson & Johnson$867
E.r. Squibb & Sons, L.L.C.$771
Merck$640
Exelixis Inc.$632
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	81	$1,340
AstraZeneca(2 entities)	63	$1,146
Johnson & Johnson	46	$867
E.r. Squibb & Sons, L.L.C.	50	$771
Merck	32	$640
Exelixis Inc.	31	$632
Incyte Corporation	27	$493
Seagen Inc.	30	$439
Pfizer	24	$381
Gilead(2 entities)	20	$380
Eisai Inc.	20	$354
Takeda Pharmaceuticals U.S.A., Inc.	16	$346
AbbVie	15	$345
Genentech USA, Inc.	20	$340
Bristol Myers Squibb	23	$336
Sanofi	17	$320
Amgen	19	$298
Abbott	2	$275
Daiichi Sankyo Inc.	11	$247
Jazz Pharmaceuticals Inc.	12	$242
Bayer	14	$241
Beigene USA, Inc.	13	$241
Lilly USA, LLC	11	$220
Array Biopharma Inc	12	$154
Stemline Therapeutics Inc.	7	$152
EMD Serono, Inc.	5	$152
Puma Biotechnology, Inc.	9	$144
Karyopharm Therapeutics Inc.	6	$122
Taiho Oncology, Inc.	8	$118
GSK	7	$110
Blueprint Medicines Corporation	5	$98
Rigel Pharmaceuticals, Inc.	6	$93
Servier Pharmaceuticals LLC	4	$83
Genmab U.S., Inc.	3	$77
Pharmacyclics LLC, An Abbvie Company	4	$77
Astellas Pharma US Inc	4	$62
Sanofi-aventis U.S. LLC	4	$59
Regeneron Healthcare Solutions, Inc.	3	$57
Springworks Therapeutics, Inc.	3	$54
Sobi, Inc	3	$53
Adaptive Biotechnologies Corporation	3	$52
G1 Therapeutics, Inc.	3	$50
Geron Corporation	2	$45
Tersera Therapeutics LLC	2	$43
Beone Medicines USA, Inc.	2	$42
Boehringer Ingelheim	2	$36
Pharmaessentia USA Corporation	2	$34
Mirati Therapeutics, Inc.	2	$33
CTI Biopharma Corp.	2	$33
Kyowa Kirin, Inc.	2	$32
Roche Diagnostics Corporation	2	$30
Dendreon Pharmaceuticals LLC	1	$30
Pharmacosmos Therapeutics Inc.	2	$28
Tempus AI, Inc	1	$27
Pharming Healthcare, Inc.	1	$22
Deciphera Pharmaceuticals Inc.	1	$22
Cycle Pharmaceuticals Inc	1	$22
Nuvation Bio Inc.	1	$21
Dova Pharmaceuticals	1	$19
Legend Biotech USA Inc.	1	$18

How this compares

$13,280 in reported general payments places this provider in the 50th percentile of 54 hematology & oncology providers in New Mexico.

See all hematology & oncology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$2,075,777

Medicare patients

330

Services billed

79,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Santa Fe

Karen LorussoSanta Fe$302K
Kathryn ChanSanta Fe$11K
Timothy LopezSanta Fe$3K
Ursa Brown GlabermanAlbuquerque$5M
Neda Hashemi SadraeiAlbuquerque$1.6M
Olivier RixeAlbuquerque$1.6M
Jeffrey NeidhartFarmington$1.5M
Emrullah YilmazAlbuquerque$1.3M
Erika MaestasAlbuquerque$880K
Sardar ImamFarmington$647K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →